Vol. 2 No. 10 (2022)
Reimbursement Reviews

Sodium Phenylbutyrate-Ursodoxicoltaurine (Albrioza)

Published October 21, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Sodium phenylbutyrate-ursodoxicoltaurine (Albrioza), 3 g/1 g per sachet, powder for oral suspension.
  • Indication (proposed): For the treatment of amyotrophic lateral sclerosis.